We hypothesized that FOXD1 might transcriptionally activate BNIP3 expression, thereby promoting mitophagy and malignant progression in NPC cells, potentially leading to insensitivity to chemotherapeutic drugs. This evidence concerns the gene FOXD1 and nasopharyngeal carcinoma.